Learn more about the latest advancements in the treatment of Thyroid Eye Disease (TED) in this presentation by Dr. Kimberly Cockerham. She discusses the findings from the THRIVE-2 Phase 3 Veligrotug Trial, focusing on efficacy, safety, and quality of life outcomes at 15 weeks.
Dr. Kimberly Cockerham Discusses New Findings in Chronic Thyroid Eye Disease Treatment
Recent Posts
Better Understanding Thyroid Eye Disease
March 15, 2024
Annenberg Center for Health Sciences
March 15, 2024
A New Breakthrough in Thyroid Eye Disease
March 15, 2024
New Website Launch
February 13, 2024